Baird Maintains Outperform on Definium Therapeutics, Raises Price Target to $57
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
Baird analyst Christopher Chen maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and raises the price target from $37 to $57.
Baird analyst Christopher Chen maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and raises the price target from $37 to $57.